Nanobiotix Files Routine 6-K Report
Ticker: NBTX · Form: 6-K · Filed: Dec 9, 2024 · CIK: 1760854
Sentiment: neutral
Topics: sec-filing, 6-k, routine-report
TL;DR
Nanobiotix filed a 6-K, just routine paperwork, no big news.
AI Summary
Nanobiotix S.A. filed a Form 6-K on December 9, 2024, reporting for the month of December 2024. The company, based in Paris, France, is a foreign private issuer and files annual reports under Form 20-F. This filing does not appear to contain specific financial or operational updates beyond its routine reporting status.
Why It Matters
This filing indicates Nanobiotix is fulfilling its regular reporting obligations as a foreign private issuer with the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — This is a routine filing by a foreign private issuer and does not contain new material information or significant financial events.
Key Players & Entities
- Nanobiotix S.A. (company) — Registrant
- 001-39777 (company) — SEC File Number
- 20241209 (date) — Filing Date
- 60 Rue de Wattignies 75012 Paris, France (company) — Principal Executive Office Address
FAQ
What type of filing is this Form 6-K?
This is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Who is the filer of this report?
The filer is Nanobiotix S.A.
What is the Commission File Number for Nanobiotix S.A.?
The Commission File Number is 001-39777.
Where is Nanobiotix S.A. located?
Nanobiotix S.A. is located at 60 Rue de Wattignies, 75012 Paris, France.
Does Nanobiotix S.A. file its annual reports under Form 20-F or Form 40-F?
Nanobiotix S.A. files its annual reports under cover of Form 20-F.
Filing Stats: 172 words · 1 min read · ~1 pages · Grade level 9.1 · Accepted 2024-12-09 16:15:04
Filing Documents
- f6k_120924.htm (6-K) — 5KB
- exh_991.htm (EX-99.1) — 11KB
- 0001171843-24-006825.txt ( ) — 17KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Nanobiotix S.A. (Registrant) Date: December 9, 2024 /s/ Bart Van Rhijn Bart Van Rhijn Chief Financial Officer